Generic Medicine Info
Indications and Dosage
Susceptible infections, Respiratory tract infections, Abdominal infections, Skin and soft tissue infections, Pelvic infections, Bacterial endocarditis, Peritonitis, Septicaemia, Biliary tract infections
Adult: Serious infections: 200-300 mg/kg/day in divided doses. Life-threatening infections: Up to 350 mg/kg/day. Max: 24 g/day.

Prophylaxis of infection during surgery
Adult: 4 g pre-operatively, followed by 2 further doses every 6 hr.

Uncomplicated gonorrhoea
Adult: 1-2 g IM/IV as a single dose. Probenecid 1 g may be given orally at the same time or up to 30 min before the inj.

Uncomplicated urinary tract infections
Adult: 1.5-2 g IM/IV every 6 hr.
Renal Impairment
Dose reduction may be necessary.
Hypersensitivity to penicillins.
Special Precautions
Patients on restricted sodium diet. Avoid contact; skin sensitisation may occur. Monitor serum potassium concentration, renal, hepatic and haematological status during prolonged therapy. Spirochete infections particularly syphilis. Suprainfection with penicillin-resistant organisms may occur with prolonged use. Avoid intrathecal route. Pregnancy and lactation.
Adverse Reactions
Diarrhoea, nausea, vomiting, pseudomembranous enterocolitis, hypersensitivity reactions. Rarely prolonged bleeding time, mucosal bleeding, purpura. Anxiety, muscle cramps and convulsions (high doses). Pain at inj site and phlebitis. Increased LFTs, hypokalaemia, elevated bilirubin, creatinine.
Potentially Fatal: Anaphylaxis.
IM/IV/Parenteral: B
Symptoms: Rash, fever, chills, peeling skin.
Drug Interactions
Probenecid may inhibit renal excretion of mezlocillin. Monitor blood coagulation parameters when used with high-dose heparin and other anticoagulants.
Lab Interference
May interfere with diagnostic tests for urinary glucose using copper sulfate, direct Coombs' test, and test for urinary or serum proteins. May interfere with diagnostic tests that use bacteria.
Mechanism of Action: Mezlocillin, a broad-spectrum ureidopenicillin, blocks the final cross-linking stage of peptidoglycan production through binding and inactivation of transpeptidases thus inhibiting bacterial cell wall synthesis. It is active against a wide range of gram-negative organisms, but is less active against P. aeruginosa compared to azlocillin or piperacillin.
Absorption: Not significantly absorbed from the GI tract. Well absorbed after IM inj, with peak plasma concentrations in 45-90 min.
Distribution: Protein-binding: 16-42%. Widely distributed in body tissues and fluids; crosses the placenta and distributed into breast milk (small amounts). Minimal diffusion into CSF.
Metabolism: Limited.
Excretion: Via urine by glomerular filtration and tubular secretion (about 55% of total dose, as unchanged drug); via bile (up to 30%). Half-life: Approx 1 hr; slightly prolonged in neonates; up to 6 hr in patients with renal impairment.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Mezlocillin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in